drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00180 | DB00701 | 1,351 | 1,091 | [
"DDInter749",
"DDInter90"
] | Flunisolide | Amprenavir | Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. | Amprenavir is a protease inhibitor used to treat HIV infection. | Moderate | 1 | [
[
[
1351,
24,
1091
]
],
[
[
1351,
24,
34
],
[
34,
1,
1091
]
],
[
[
1351,
6,
8374
],
[
8374,
45,
1091
]
],
[
[
1351,
21,
28996
],
[
28996,
... | [
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
],
... | Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir (Compound) resembles Amprenavir (Compound)
Flunisolide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Amprenavir (Compound)
Flunisolide (Compound) causes Musculoskeletal discomfort (... |
DB01068 | DB01612 | 1,565 | 1,637 | [
"DDInter411",
"DDInter92"
] | Clonazepam | Amyl Nitrite | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
1565,
24,
1637
]
],
[
[
1565,
1,
1216
],
[
1216,
24,
1637
]
],
[
[
1565,
64,
475
],
[
475,
24,
1637
]
],
[
[
1565,
24,
401
],
[
401,
... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
],
[
"Flurazepam",
"{u} may cause a moder... | Clonazepam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Clonazepam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate disea... |
DB01209 | DB09472 | 1,359 | 1,383 | [
"DDInter531",
"DDInter1693"
] | Dezocine | Sodium sulfate | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1359,
24,
1383
]
],
[
[
1359,
24,
1311
],
[
1311,
24,
1383
]
],
[
[
1359,
63,
1133
],
[
1133,
24,
1383
]
],
[
[
1359,
64,
475
],
[
475... | [
[
[
"Dezocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Dezocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
... | Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron a... |
DB00377 | DB01166 | 1,494 | 477 | [
"DDInter1382",
"DDInter379"
] | Palonosetron | Cilostazol | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1494,
24,
477
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1494,
21,
28688
],
[
28688,
60,
477
]
],
[
[
1494,
23,
112
],
[
112,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Palonosetron (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Cilostazol (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole a... |
DB00366 | DB00719 | 1,594 | 1,219 | [
"DDInter600",
"DDInter149"
] | Doxylamine | Azatadine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
1594,
24,
1219
]
],
[
[
1594,
24,
13
],
[
13,
24,
1219
]
],
[
[
1594,
24,
830
],
[
830,
1,
1219
]
],
[
[
1594,
63,
695
],
[
695,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine a... |
DB00005 | DB06772 | 1,057 | 310 | [
"DDInter687",
"DDInter259"
] | Etanercept | Cabazitaxel | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Major | 2 | [
[
[
1057,
25,
310
]
],
[
[
1057,
25,
973
],
[
973,
24,
310
]
],
[
[
1057,
25,
800
],
[
800,
63,
310
]
],
[
[
1057,
24,
458
],
[
458,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} ... | Etanercept may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Etanercept may lead to a major life threatening interaction when taken with Duvelisib and Duvelisib may cause a moderate inter... |
DB00341 | DB09118 | 1,242 | 1,580 | [
"DDInter343",
"DDInter1711"
] | Cetirizine | Stiripentol | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1242,
24,
1580
]
],
[
[
1242,
24,
1532
],
[
1532,
24,
1580
]
],
[
[
1242,
24,
407
],
[
407,
63,
1580
]
],
[
[
1242,
74,
701
],
[
701,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may ... |
DB00108 | DB00443 | 1,066 | 251 | [
"DDInter1268",
"DDInter195"
] | Natalizumab | Betamethasone | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Major | 2 | [
[
[
1066,
25,
251
]
],
[
[
1066,
25,
617
],
[
617,
40,
251
]
],
[
[
1066,
25,
870
],
[
870,
1,
251
]
],
[
[
1066,
23,
1461
],
[
1461,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betamethasone"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"... | Natalizumab may lead to a major life threatening interaction when taken with Budesonide and Budesonide (Compound) resembles Betamethasone (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betamethasone (Compound)
Natalizumab ... |
DB00679 | DB12245 | 684 | 823 | [
"DDInter1796",
"DDInter1863"
] | Thioridazine | Triclabendazole | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
684,
25,
823
]
],
[
[
684,
23,
112
],
[
112,
23,
823
]
],
[
[
684,
64,
1010
],
[
1010,
24,
823
]
],
[
[
684,
24,
28
],
[
28,
24,... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Thioridazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"... | Thioridazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Thioridazine may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine... |
DB00976 | DB08916 | 1,056 | 26 | [
"DDInter1758",
"DDInter32"
] | Telithromycin | Afatinib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
1056,
24,
26
]
],
[
[
1056,
63,
883
],
[
883,
40,
26
]
],
[
[
1056,
21,
28809
],
[
28809,
60,
26
]
],
[
[
1056,
25,
124
],
[
124,
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[... | Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Telithromycin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Afatinib (Compound)
Telithromycin may lead to a major life threa... |
DB00719 | DB01174 | 1,219 | 697 | [
"DDInter149",
"DDInter1442"
] | Azatadine | Phenobarbital | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
1219,
24,
697
]
],
[
[
1219,
24,
759
],
[
759,
1,
697
]
],
[
[
1219,
63,
362
],
[
362,
1,
697
]
],
[
[
1219,
63,
536
],
[
536,
4... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
... |
DB01211 | DB01309 | 609 | 1,254 | [
"DDInter393",
"DDInter933"
] | Clarithromycin | Insulin glulisine | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
609,
24,
1254
]
],
[
[
609,
64,
1424
],
[
1424,
24,
1254
]
],
[
[
609,
63,
167
],
[
167,
24,
1254
]
],
[
[
609,
24,
1220
],
[
1220,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
... | Clarithromycin may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocor... |
DB00431 | DB00685 | 1,503 | 1,299 | [
"DDInter1072",
"DDInter1887"
] | Lindane | Trovafloxacin | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Moderate | 1 | [
[
[
1503,
24,
1299
]
],
[
[
1503,
24,
872
],
[
872,
40,
1299
]
],
[
[
1503,
21,
28719
],
[
28719,
60,
1299
]
],
[
[
1503,
63,
1648
],
[
16... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[
... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Lindane (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Trovafloxacin (Compound)
Lindane may cause a moderate interaction that coul... |
DB00330 | DB01097 | 238 | 1,377 | [
"DDInter689",
"DDInter1033"
] | Ethambutol | Leflunomide | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
238,
25,
1377
]
],
[
[
238,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
238,
24,
597
],
[
597,
24,
1377
]
],
[
[
238,
24,
1434
],
[
1434,
... | [
[
[
"Ethambutol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Ethambutol",
"{u} (Compound) causes {v} (Side Effect)",
"Neutropenia"
],
[
"Neutropenia",
"{u} (Side Effect) is caused by {v} ... | Ethambutol (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when tak... |
DB00622 | DB14724 | 1,081 | 48 | [
"DDInter1287",
"DDInter634"
] | Nicardipine | Emapalumab | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
1081,
24,
48
]
],
[
[
1081,
40,
376
],
[
376,
24,
48
]
],
[
[
1081,
24,
1456
],
[
1456,
24,
48
]
],
[
[
1081,
40,
376
],
[
376,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Amlodipine"
],
[
"Amlodipine",
"{u} may cause a moder... | Nicardipine (Compound) resembles Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that cou... |
DB01259 | DB08901 | 392 | 1,468 | [
"DDInter1024",
"DDInter1492"
] | Lapatinib | Ponatinib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
392,
24,
1468
]
],
[
[
392,
25,
478
],
[
478,
24,
1468
]
],
[
[
392,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
392,
18,
20113
],
[
20113,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
... | Lapatinib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Lapatinib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Lapatinib (Compound) downregulates IER3... |
DB00422 | DB00852 | 895 | 1,445 | [
"DDInter1189",
"DDInter1545"
] | Methylphenidate | Pseudoephedrine | Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cogni... | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Moderate | 1 | [
[
[
895,
24,
1445
]
],
[
[
895,
40,
904
],
[
904,
40,
1445
]
],
[
[
895,
24,
22
],
[
22,
40,
1445
]
],
[
[
895,
6,
7390
],
[
7390,
4... | [
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Methylphenidate",
"{u} (Compound) resembles {v} (Compound)",
"Cyclandelate"
],
[
"Cyclandelate",
"{u} ... | Methylphenidate (Compound) resembles Cyclandelate (Compound) and Cyclandelate (Compound) resembles Pseudoephedrine (Compound)
Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Pseudoephedrine (Compound)
Methylphenidate (Compound)... |
DB00448 | DB00641 | 1,215 | 467 | [
"DDInter1022",
"DDInter1675"
] | Lansoprazole | Simvastatin | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Moderate | 1 | [
[
[
1215,
24,
467
]
],
[
[
1215,
6,
8374
],
[
8374,
45,
467
]
],
[
[
1215,
18,
4112
],
[
4112,
57,
467
]
],
[
[
1215,
21,
29404
],
[
29404... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Lansoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Lansoprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Simvastatin (Compound)
Lansoprazole (Compound) downregulates AURKB (Gene) and AURKB (Gene) is downregulated by Simvastatin (Compound)
Lansoprazole (Compound) causes Cataract (Side Effect) and Cataract (Side Effect) is caused by Simvastatin (Compo... |
DB00108 | DB01005 | 1,066 | 995 | [
"DDInter1268",
"DDInter894"
] | Natalizumab | Hydroxyurea | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Major | 2 | [
[
[
1066,
25,
995
]
],
[
[
1066,
25,
1238
],
[
1238,
24,
995
]
],
[
[
1066,
25,
869
],
[
869,
63,
995
]
],
[
[
1066,
64,
1648
],
[
1648,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"... | Natalizumab may lead to a major life threatening interaction when taken with Pentostatin and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Natalizumab may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate i... |
DB01132 | DB05528 | 1,130 | 1,070 | [
"DDInter1472",
"DDInter1228"
] | Pioglitazone | Mipomersen | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1130,
25,
1070
]
],
[
[
1130,
24,
1250
],
[
1250,
64,
1070
]
],
[
[
1130,
63,
168
],
[
168,
25,
1070
]
],
[
[
1130,
24,
609
],
[
609,
... | [
[
[
"Pioglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopan... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Mipomersen
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may lead... |
DB00358 | DB01268 | 1,010 | 1,151 | [
"DDInter1140",
"DDInter1731"
] | Mefloquine | Sunitinib | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1010,
24,
1151
]
],
[
[
1010,
23,
1311
],
[
1311,
1,
1151
]
],
[
[
1010,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
1010,
7,
9650
],
[
9650,... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoclopramide"
],
[
... | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Mefloquine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Mefloquine (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene... |
DB00569 | DB04865 | 553 | 4 | [
"DDInter775",
"DDInter1335"
] | Fondaparinux | Omacetaxine mepesuccinate | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
553,
25,
4
]
],
[
[
553,
63,
305
],
[
305,
24,
4
]
],
[
[
553,
24,
738
],
[
738,
63,
4
]
],
[
[
553,
25,
39
],
[
39,
63,
4... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichi... | Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fondaparinux may cause a moderate interaction that could ... |
DB00046 | DB00679 | 1,179 | 684 | [
"DDInter940",
"DDInter1796"
] | Insulin lispro | Thioridazine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Moderate | 1 | [
[
[
1179,
24,
684
]
],
[
[
1179,
24,
146
],
[
146,
40,
684
]
],
[
[
1179,
24,
216
],
[
216,
1,
684
]
],
[
[
1179,
24,
417
],
[
417,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles Thioridazine (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles ... |
DB04835 | DB11730 | 1,655 | 351 | [
"DDInter1125",
"DDInter1588"
] | Maraviroc | Ribociclib | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1655,
24,
351
]
],
[
[
1655,
24,
283
],
[
283,
62,
351
]
],
[
[
1655,
63,
597
],
[
597,
24,
351
]
],
[
[
1655,
24,
951
],
[
951,
... | [
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chlor... |
DB00290 | DB01004 | 329 | 563 | [
"DDInter219",
"DDInter806"
] | Bleomycin | Ganciclovir | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
329,
24,
563
]
],
[
[
329,
24,
248
],
[
248,
40,
563
]
],
[
[
329,
21,
28645
],
[
28645,
60,
563
]
],
[
[
329,
63,
552
],
[
552,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Bleomycin (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Ganciclovir (Compound)
Bleomycin may cause a moderate interaction t... |
DB00398 | DB14881 | 79 | 180 | [
"DDInter1702",
"DDInter1329"
] | Sorafenib | Oliceridine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
79,
24,
180
]
],
[
[
79,
23,
112
],
[
112,
23,
180
]
],
[
[
79,
24,
401
],
[
401,
24,
180
]
],
[
[
79,
63,
618
],
[
618,
24,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Pro... |
DB00280 | DB00332 | 494 | 1,089 | [
"DDInter575",
"DDInter970"
] | Disopyramide | Ipratropium | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Moderate | 1 | [
[
[
494,
24,
1089
]
],
[
[
494,
63,
352
],
[
352,
24,
1089
]
],
[
[
494,
24,
85
],
[
85,
63,
1089
]
],
[
[
494,
6,
4304
],
[
4304,
4... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipratropium"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropin... |
DB00106 | DB01211 | 618 | 609 | [
"DDInter4",
"DDInter393"
] | Abarelix | Clarithromycin | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
618,
24,
609
]
],
[
[
618,
24,
1570
],
[
1570,
24,
609
]
],
[
[
618,
24,
600
],
[
600,
23,
609
]
],
[
[
618,
23,
1247
],
[
1247,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and F... |
DB11837 | DB11986 | 1,297 | 484 | [
"DDInter1351",
"DDInter648"
] | Osilodrostat | Entrectinib | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1297,
24,
484
]
],
[
[
1297,
62,
1247
],
[
1247,
23,
484
]
],
[
[
1297,
23,
466
],
[
466,
62,
484
]
],
[
[
1297,
63,
1539
],
[
1539,
... | [
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],... | Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Darolutami... |
DB00938 | DB01261 | 455 | 170 | [
"DDInter1635",
"DDInter1679"
] | Salmeterol | Sitagliptin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
455,
24,
170
]
],
[
[
455,
6,
3486
],
[
3486,
45,
170
]
],
[
[
455,
21,
28850
],
[
28850,
60,
170
]
],
[
[
455,
24,
52
],
[
52,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)"... | Salmeterol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sitagliptin (Compound)
Salmeterol (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and D... |
DB00358 | DB00916 | 1,010 | 112 | [
"DDInter1140",
"DDInter1202"
] | Mefloquine | Metronidazole | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
1010,
23,
112
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
112
]
],
[
[
1010,
21,
29028
],
[
29028,
60,
112
]
],
[
[
1010,
63,
847
],
[
847,
... | [
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound)
Mefloquine (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Metronidazole (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Ato... |
DB01030 | DB11627 | 869 | 1,367 | [
"DDInter1835",
"DDInter860"
] | Topotecan | Hepatitis B Vaccine (Recombinant) | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
869,
24,
1367
]
],
[
[
869,
63,
1083
],
[
1083,
24,
1367
]
],
[
[
869,
24,
1480
],
[
1480,
24,
1367
]
],
[
[
869,
24,
119
],
[
119,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triflu... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Topotecan may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00242 | DB00532 | 1,064 | 208 | [
"DDInter392",
"DDInter1152"
] | Cladribine | Mephenytoin | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Major | 2 | [
[
[
1064,
25,
208
]
],
[
[
1064,
64,
168
],
[
168,
23,
208
]
],
[
[
1064,
25,
1096
],
[
1096,
62,
208
]
],
[
[
1064,
24,
1613
],
[
1613,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mephenytoin"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} ... | Cladribine may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Mephenytoin
Cladribine may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a ... |
DB00046 | DB00841 | 1,179 | 532 | [
"DDInter940",
"DDInter577"
] | Insulin lispro | Dobutamine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Moderate | 1 | [
[
[
1179,
24,
532
]
],
[
[
1179,
24,
817
],
[
817,
40,
532
]
],
[
[
1179,
24,
1052
],
[
1052,
1,
532
]
],
[
[
1179,
24,
123
],
[
123,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Dobutamine (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine (Compound) resembles Dobutamine (Compound... |
DB01041 | DB08826 | 770 | 1,292 | [
"DDInter1789",
"DDInter489"
] | Thalidomide | Deferiprone | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
770,
25,
1292
]
],
[
[
770,
7,
6858
],
[
6858,
46,
1292
]
],
[
[
770,
21,
29124
],
[
29124,
60,
1292
]
],
[
[
770,
63,
45
],
[
45,
... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Thalidomide",
"{u} (Compound) upregulates {v} (Gene)",
"LPL"
],
[
"LPL",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Thalidomide (Compound) upregulates LPL (Gene) and LPL (Gene) is upregulated by Deferiprone (Compound)
Thalidomide (Compound) causes Rash pustular (Side Effect) and Rash pustular (Side Effect) is caused by Deferiprone (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00039 | DB01101 | 1,253 | 60 | [
"DDInter1380",
"DDInter285"
] | Palifermin | Capecitabine | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
1253,
24,
60
]
],
[
[
1253,
24,
309
],
[
309,
62,
60
]
],
[
[
1253,
24,
147
],
[
147,
23,
60
]
],
[
[
1253,
24,
599
],
[
599,
24... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vin... |
DB00963 | DB09472 | 1,263 | 1,383 | [
"DDInter241",
"DDInter1693"
] | Bromfenac | Sodium sulfate | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1263,
24,
1383
]
],
[
[
1263,
24,
1613
],
[
1613,
24,
1383
]
],
[
[
1263,
25,
1618
],
[
1618,
24,
1383
]
],
[
[
1263,
63,
912
],
[
912... | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Bromfenac may lead to a major life threatening interaction when taken with Cabozantinib... |
DB00059 | DB00208 | 1,560 | 1,018 | [
"DDInter1404",
"DDInter1804"
] | Pegaspargase | Ticlopidine | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Moderate | 1 | [
[
[
1560,
24,
1018
]
],
[
[
1560,
24,
1347
],
[
1347,
64,
1018
]
],
[
[
1560,
24,
1486
],
[
1486,
62,
1018
]
],
[
[
1560,
24,
1027
],
[
10... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methyl... |
DB00776 | DB09065 | 1,335 | 760 | [
"DDInter1360",
"DDInter424"
] | Oxcarbazepine | Cobicistat | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1335,
24,
760
]
],
[
[
1335,
62,
1101
],
[
1101,
23,
760
]
],
[
[
1335,
24,
1041
],
[
1041,
24,
760
]
],
[
[
1335,
63,
1195
],
[
1195,... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
... | Oxcarbazepine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol and Pa... |
DB01156 | DB04908 | 593 | 1,671 | [
"DDInter252",
"DDInter741"
] | Bupropion | Flibanserin | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
593,
24,
1671
]
],
[
[
593,
25,
407
],
[
407,
63,
1671
]
],
[
[
593,
24,
850
],
[
850,
63,
1671
]
],
[
[
593,
62,
752
],
[
752,
... | [
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{... | Bupropion may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may... |
DB01259 | DB06288 | 392 | 607 | [
"DDInter1024",
"DDInter77"
] | Lapatinib | Amisulpride | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
392,
25,
607
]
],
[
[
392,
21,
28745
],
[
28745,
60,
607
]
],
[
[
392,
62,
112
],
[
112,
23,
607
]
],
[
[
392,
63,
1559
],
[
1559,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Lapatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Neuropathy peripheral"
],
[
"Neuropathy peripheral",
"{u} (Side Effect)... | Lapatinib (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Amisulpride (Compound)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effect... |
DB00446 | DB00474 | 597 | 1,269 | [
"DDInter351",
"DDInter1173"
] | Chloramphenicol | Methohexital | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. | Moderate | 1 | [
[
[
597,
24,
1269
]
],
[
[
597,
63,
1023
],
[
1023,
1,
1269
]
],
[
[
597,
63,
536
],
[
536,
40,
1269
]
],
[
[
597,
21,
28642
],
[
28642,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methohexital"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Methohexital (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles ... |
DB08901 | DB12834 | 1,468 | 148 | [
"DDInter1492",
"DDInter1649"
] | Ponatinib | Secnidazole | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
1468,
24,
148
]
],
[
[
1468,
63,
1593
],
[
1593,
24,
148
]
],
[
[
1468,
24,
1480
],
[
1480,
24,
148
]
],
[
[
1468,
64,
1554
],
[
1554,... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib ... |
DB00748 | DB09420 | 662 | 1,074 | [
"DDInter297",
"DDInter953"
] | Carbinoxamine | Iodide I-123 | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
662,
24,
1074
]
],
[
[
662,
24,
516
],
[
516,
24,
1074
]
],
[
[
662,
35,
849
],
[
849,
24,
1074
]
],
[
[
662,
63,
902
],
[
902,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate int... |
DB00781 | DB12615 | 1,481 | 1,381 | [
"DDInter1489",
"DDInter1482"
] | Polymyxin B | Plazomicin | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Major | 2 | [
[
[
1481,
25,
1381
]
],
[
[
1481,
25,
416
],
[
416,
24,
1381
]
],
[
[
1481,
24,
1272
],
[
1272,
24,
1381
]
],
[
[
1481,
63,
91
],
[
91,
... | [
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plazomicin"
]
],
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} m... | Polymyxin B may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may caus... |
DB00524 | DB00712 | 811 | 1,274 | [
"DDInter1199",
"DDInter763"
] | Metolazone | Flurbiprofen | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
811,
24,
1274
]
],
[
[
811,
21,
28769
],
[
28769,
60,
1274
]
],
[
[
811,
24,
842
],
[
842,
63,
1274
]
],
[
[
811,
24,
92
],
[
92,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side... | Metolazone (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exa... |
DB01124 | DB14509 | 1,411 | 1,399 | [
"DDInter1828",
"DDInter1081"
] | Tolbutamide | Lithium carbonate | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1411,
24,
1399
]
],
[
[
1411,
63,
874
],
[
874,
23,
1399
]
],
[
[
1411,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
1411,
63,
1674
],
[
1674... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide ... |
DB00812 | DB06697 | 998 | 436 | [
"DDInter1451",
"DDInter121"
] | Phenylbutazone | Artemether | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Moderate | 1 | [
[
[
998,
24,
436
]
],
[
[
998,
6,
6017
],
[
6017,
45,
436
]
],
[
[
998,
24,
1220
],
[
1220,
24,
436
]
],
[
[
998,
1,
804
],
[
804,
2... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Artemether"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Com... | Phenylbutazone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Artemether (Compound)
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Phen... |
DB00196 | DB01599 | 600 | 1,232 | [
"DDInter743",
"DDInter1523"
] | Fluconazole | Probucol | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Moderate | 1 | [
[
[
600,
24,
1232
]
],
[
[
600,
23,
112
],
[
112,
23,
1232
]
],
[
[
600,
24,
1555
],
[
1555,
24,
1232
]
],
[
[
600,
25,
927
],
[
927,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probucol"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Probucol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxa... |
DB00262 | DB00526 | 552 | 1,555 | [
"DDInter302",
"DDInter1355"
] | Carmustine | Oxaliplatin | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
552,
24,
1555
]
],
[
[
552,
6,
7950
],
[
7950,
45,
1555
]
],
[
[
552,
24,
141
],
[
141,
24,
1555
]
],
[
[
552,
24,
810
],
[
810,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Carmustine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)"... | Carmustine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound)
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Carmustine may... |
DB00515 | DB01229 | 589 | 973 | [
"DDInter387",
"DDInter1378"
] | Cisplatin | Paclitaxel (protein-bound) | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
589,
24,
973
]
],
[
[
589,
24,
310
],
[
310,
63,
973
]
],
[
[
589,
5,
11582
],
[
11582,
44,
973
]
],
[
[
589,
6,
6017
],
[
6017,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Cisplatin ... |
DB10795 | DB11714 | 221 | 1,316 | [
"DDInter1486",
"DDInter610"
] | Poliovirus type 1 antigen (formaldehyde inactivated) | Durvalumab | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Moderate | 1 | [
[
[
221,
24,
1316
]
],
[
[
221,
63,
167
],
[
167,
24,
1316
]
],
[
[
221,
24,
270
],
[
270,
63,
1316
]
],
[
[
221,
63,
976
],
[
976,
... | [
[
[
"Poliovirus type 1 antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Poliovirus type 1 antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction tha... | Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Poliovirus type 1 antigen (formaldehyde inactivated) may cause... |
DB00372 | DB00405 | 999 | 128 | [
"DDInter1793",
"DDInter517"
] | Thiethylperazine | Dexbrompheniramine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
999,
24,
128
]
],
[
[
999,
24,
662
],
[
662,
63,
128
]
],
[
[
999,
63,
556
],
[
556,
24,
128
]
],
[
[
999,
24,
1386
],
[
1386,
2... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbino... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00514 | DB01227 | 506 | 1,301 | [
"DDInter527",
"DDInter1043"
] | Dextromethorphan | Levacetylmethadol | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Major | 2 | [
[
[
506,
25,
1301
]
],
[
[
506,
24,
649
],
[
649,
1,
1301
]
],
[
[
506,
63,
576
],
[
576,
1,
1301
]
],
[
[
506,
6,
10969
],
[
10969,
... | [
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Levacetylmethadol (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Levac... |
DB01175 | DB05294 | 318 | 1,069 | [
"DDInter672",
"DDInter1917"
] | Escitalopram | Vandetanib | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
318,
25,
1069
]
],
[
[
318,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
318,
21,
28719
],
[
28719,
60,
1069
]
],
[
[
318,
63,
660
],
[
660,
... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Van... | Escitalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Escitalopram (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Vandetanib (Compound)
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomep... |
DB09034 | DB11186 | 1,313 | 1,609 | [
"DDInter1733",
"DDInter1427"
] | Suvorexant | Pentoxyverine | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1313,
24,
1609
]
],
[
[
1313,
63,
104
],
[
104,
24,
1609
]
],
[
[
1313,
64,
475
],
[
475,
24,
1609
]
],
[
[
1313,
24,
407
],
[
407,
... | [
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Suvorexant may lead to a major life threatening interaction when taken with Morphine and Morphine may cau... |
DB00620 | DB08882 | 175 | 1,281 | [
"DDInter1855",
"DDInter1070"
] | Triamcinolone | Linagliptin | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
175,
24,
1281
]
],
[
[
175,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
175,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
175,
21,
28966
],
[
28966,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Triamcinolone (Compound) causes Upper respiratory tract in... |
DB09049 | DB11691 | 1,135 | 1,499 | [
"DDInter1261",
"DDInter1258"
] | Naloxegol | Naldemedine | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
1135,
24,
1499
]
],
[
[
1135,
62,
307
],
[
307,
23,
1499
]
],
[
[
1135,
64,
932
],
[
932,
24,
1499
]
],
[
[
1135,
63,
1159
],
[
1159,
... | [
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Naloxegol may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Naloxegol may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a m... |
DB05773 | DB06448 | 1,047 | 171 | [
"DDInter1848",
"DDInter1087"
] | Trastuzumab emtansine | Lonafarnib | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
1047,
24,
171
]
],
[
[
1047,
63,
222
],
[
222,
23,
171
]
],
[
[
1047,
63,
63
],
[
63,
24,
171
]
],
[
[
1047,
24,
310
],
[
310,
6... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibut... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB05239 | DB08903 | 866 | 996 | [
"DDInter425",
"DDInter170"
] | Cobimetinib | Bedaquiline | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
866,
24,
996
]
],
[
[
866,
24,
713
],
[
713,
63,
996
]
],
[
[
866,
63,
353
],
[
353,
24,
996
]
],
[
[
866,
25,
283
],
[
283,
63,... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Gris... |
DB00857 | DB01069 | 1,387 | 401 | [
"DDInter1768",
"DDInter1533"
] | Terbinafine | Promethazine | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1387,
24,
401
]
],
[
[
1387,
63,
146
],
[
146,
24,
401
]
],
[
[
1387,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1387,
24,
104
],
[
104,
... | [
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
... | Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and D... |
DB04845 | DB12267 | 309 | 1,476 | [
"DDInter1001",
"DDInter233"
] | Ixabepilone | Brigatinib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
309,
24,
1476
]
],
[
[
309,
63,
168
],
[
168,
23,
1476
]
],
[
[
309,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
309,
24,
800
],
[
800,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra... |
DB00213 | DB00562 | 837 | 1,014 | [
"DDInter1388",
"DDInter188"
] | Pantoprazole | Benzthiazide | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Moderate | 1 | [
[
[
837,
24,
1014
]
],
[
[
837,
24,
811
],
[
811,
40,
1014
]
],
[
[
837,
24,
674
],
[
674,
1,
1014
]
],
[
[
837,
24,
126
],
[
126,
6... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Benzthiazide (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles ... |
DB00661 | DB06663 | 122 | 1,154 | [
"DDInter1928",
"DDInter1398"
] | Verapamil | Pasireotide | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
122,
24,
1154
]
],
[
[
122,
63,
966
],
[
966,
40,
1154
]
],
[
[
122,
21,
28898
],
[
28898,
60,
1154
]
],
[
[
122,
23,
466
],
[
466,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Verapamil (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pasireotide (Compound)
Verapamil may cause a minor interactio... |
DB01234 | DB11952 | 1,220 | 800 | [
"DDInter513",
"DDInter612"
] | Dexamethasone | Duvelisib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
1220,
24,
800
]
],
[
[
1220,
25,
466
],
[
466,
62,
800
]
],
[
[
1220,
25,
1476
],
[
1476,
63,
800
]
],
[
[
1220,
63,
663
],
[
663,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Dar... | Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Dexamethasone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a modera... |
DB00352 | DB00584 | 482 | 610 | [
"DDInter1814",
"DDInter638"
] | Tioguanine | Enalapril | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Moderate | 1 | [
[
[
482,
24,
610
]
],
[
[
482,
24,
743
],
[
743,
1,
610
]
],
[
[
482,
24,
954
],
[
954,
40,
610
]
],
[
[
482,
21,
28826
],
[
28826,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) resembles Enalapril (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Enalapril (Compound)
Tiog... |
DB00673 | DB01118 | 723 | 33 | [
"DDInter112",
"DDInter76"
] | Aprepitant | Amiodarone | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
723,
24,
33
]
],
[
[
723,
24,
540
],
[
540,
1,
33
]
],
[
[
723,
6,
7950
],
[
7950,
45,
33
]
],
[
[
723,
54,
19146
],
[
19146,
15... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Aprepitant (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound)
Aprepitant (Compound) is included by Cytochrome P450 3A4 Inhibit... |
DB00363 | DB08875 | 695 | 1,618 | [
"DDInter419",
"DDInter262"
] | Clozapine | Cabozantinib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
695,
25,
1618
]
],
[
[
695,
23,
112
],
[
112,
23,
1618
]
],
[
[
695,
25,
384
],
[
384,
63,
1618
]
],
[
[
695,
25,
1668
],
[
1668,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Clozapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Clozapine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may caus... |
DB00425 | DB11186 | 558 | 1,609 | [
"DDInter1970",
"DDInter1427"
] | Zolpidem | Pentoxyverine | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
558,
24,
1609
]
],
[
[
558,
24,
649
],
[
649,
24,
1609
]
],
[
[
558,
63,
701
],
[
701,
24,
1609
]
],
[
[
558,
64,
475
],
[
475,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemast... |
DB00928 | DB14444 | 1,426 | 151 | [
"DDInter148",
"DDInter924"
] | Azacitidine | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1426,
24,
151
]
],
[
[
1426,
63,
66
],
[
66,
24,
151
]
],
[
[
1426,
24,
869
],
[
869,
24,
151
]
],
[
[
1426,
25,
375
],
[
375,
2... | [
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could... | Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Azacitidine may cause a moderate int... |
DB06290 | DB11691 | 1,449 | 1,499 | [
"DDInter1673",
"DDInter1258"
] | Simeprevir | Naldemedine | Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, an... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
1449,
24,
1499
]
],
[
[
1449,
64,
600
],
[
600,
24,
1499
]
],
[
[
1449,
25,
283
],
[
283,
63,
1499
]
],
[
[
1449,
25,
1456
],
[
1456,
... | [
[
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Simeprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconaz... | Simeprevir may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Simeprevir may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate i... |
DB00701 | DB06203 | 1,091 | 1,002 | [
"DDInter90",
"DDInter51"
] | Amprenavir | Alogliptin | Amprenavir is a protease inhibitor used to treat HIV infection. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1091,
24,
1002
]
],
[
[
1091,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1091,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
1091,
21,
29340
],
[
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Amprenavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Amprenavir (Compound) causes Stevens-Johnson syndrome (Side Effe... |
DB00757 | DB00802 | 1,166 | 1,322 | [
"DDInter581",
"DDInter43"
] | Dolasetron | Alfentanil | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Major | 2 | [
[
[
1166,
25,
1322
]
],
[
[
1166,
25,
411
],
[
411,
1,
1322
]
],
[
[
1166,
64,
1454
],
[
1454,
1,
1322
]
],
[
[
1166,
6,
8374
],
[
8374,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alfentanil"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Remifentanil"
],
[
"Remifentanil",
"{... | Dolasetron may lead to a major life threatening interaction when taken with Remifentanil and Remifentanil (Compound) resembles Alfentanil (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Sufentanil and Sufentanil (Compound) resembles Alfentanil (Compound)
Dolasetron (Compound) bind... |
DB00086 | DB00861 | 1,167 | 914 | [
"DDInter1712",
"DDInter551"
] | Streptokinase | Diflunisal | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Moderate | 1 | [
[
[
1167,
24,
914
]
],
[
[
1167,
25,
1564
],
[
1564,
63,
914
]
],
[
[
1167,
24,
1061
],
[
1061,
24,
914
]
],
[
[
1167,
64,
366
],
[
366,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Def... | Streptokinase may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostini... |
DB00451 | DB01067 | 542 | 959 | [
"DDInter1064",
"DDInter826"
] | Levothyroxine | Glipizide | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
542,
24,
959
]
],
[
[
542,
63,
245
],
[
245,
40,
959
]
],
[
[
542,
24,
1411
],
[
1411,
1,
959
]
],
[
[
542,
6,
8374
],
[
8374,
4... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Co... |
DB00261 | DB06788 | 702 | 1,616 | [
"DDInter93",
"DDInter864"
] | Anagrelide | Histrelin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Major | 2 | [
[
[
702,
25,
1616
]
],
[
[
702,
23,
112
],
[
112,
23,
1616
]
],
[
[
702,
25,
1664
],
[
1664,
24,
1616
]
],
[
[
702,
24,
603
],
[
603,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Anagrelide may lead to a major life threatening interaction when taken with Risperidone and Risperidone may cau... |
DB01268 | DB06218 | 1,151 | 136 | [
"DDInter1731",
"DDInter1014"
] | Sunitinib | Lacosamide | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of interaction with sodium channels. Lacosamide was first approved by the European Commissio... | Moderate | 1 | [
[
[
1151,
24,
136
]
],
[
[
1151,
63,
633
],
[
633,
40,
136
]
],
[
[
1151,
63,
1144
],
[
1144,
1,
136
]
],
[
[
1151,
21,
29076
],
[
29076,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lacosamide"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
],
... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Lisdexamfetamine and Lisdexamfetamine (Compound) resembles Lacosamide (Compound)
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) resembles Lacosamide... |
DB00013 | DB09068 | 1,255 | 1,427 | [
"DDInter1905",
"DDInter1948"
] | Urokinase | Vortioxetine | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1255,
24,
1427
]
],
[
[
1255,
25,
256
],
[
256,
24,
1427
]
],
[
[
1255,
24,
477
],
[
477,
24,
1427
]
],
[
[
1255,
25,
405
],
[
405,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",... | Urokinase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a ... |
DB00377 | DB01087 | 1,494 | 1,520 | [
"DDInter1382",
"DDInter1520"
] | Palonosetron | Primaquine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
1494,
24,
1520
]
],
[
[
1494,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
1494,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
1494,
21,
28722
],
[
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
... | Palonosetron may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Palonosetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Palonosetron (Compound) caus... |
DB00619 | DB14975 | 1,419 | 988 | [
"DDInter909",
"DDInter1949"
] | Imatinib | Voxelotor | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
1419,
24,
988
]
],
[
[
1419,
23,
222
],
[
222,
23,
988
]
],
[
[
1419,
24,
466
],
[
466,
23,
988
]
],
[
[
1419,
63,
251
],
[
251,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"S... | Imatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamid... |
DB00554 | DB05578 | 1,027 | 330 | [
"DDInter1478",
"DDInter1566"
] | Piroxicam | Ramucirumab | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
1027,
25,
330
]
],
[
[
1027,
24,
384
],
[
384,
63,
330
]
],
[
[
1027,
24,
222
],
[
222,
24,
330
]
],
[
[
1027,
24,
1317
],
[
1317,
... | [
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib"... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutr... |
DB09078 | DB14509 | 1,228 | 1,399 | [
"DDInter1036",
"DDInter1081"
] | Lenvatinib | Lithium carbonate | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1228,
24,
1399
]
],
[
[
1228,
63,
1374
],
[
1374,
24,
1399
]
],
[
[
1228,
24,
927
],
[
927,
24,
1399
]
],
[
[
1228,
62,
112
],
[
112,
... | [
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
... | Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib ... |
DB01050 | DB08895 | 848 | 976 | [
"DDInter900",
"DDInter1825"
] | Ibuprofen | Tofacitinib | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
848,
24,
976
]
],
[
[
848,
24,
1017
],
[
1017,
63,
976
]
],
[
[
848,
63,
723
],
[
723,
24,
976
]
],
[
[
848,
24,
699
],
[
699,
2... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepit... |
DB00352 | DB01211 | 482 | 609 | [
"DDInter1814",
"DDInter393"
] | Tioguanine | Clarithromycin | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
482,
24,
609
]
],
[
[
482,
63,
1570
],
[
1570,
24,
609
]
],
[
[
482,
21,
28658
],
[
28658,
60,
609
]
],
[
[
482,
63,
600
],
[
600,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Tioguanine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Clarithromyc... |
DB00791 | DB14783 | 132 | 287 | [
"DDInter1902",
"DDInter574"
] | Uracil mustard | Diroximel fumarate | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
132,
24,
287
]
],
[
[
132,
24,
384
],
[
384,
24,
287
]
],
[
[
132,
63,
599
],
[
599,
24,
287
]
],
[
[
132,
1,
970
],
[
970,
24,
... | [
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"... | Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Alemt... |
DB00994 | DB01250 | 361 | 712 | [
"DDInter1277",
"DDInter1334"
] | Neomycin | Olsalazine | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
361,
24,
712
]
],
[
[
361,
63,
50
],
[
50,
40,
712
]
],
[
[
361,
24,
279
],
[
279,
23,
712
]
],
[
[
361,
63,
126
],
[
126,
23,
... | [
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
... | Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a minor interaction that can ... |
DB00213 | DB01045 | 837 | 463 | [
"DDInter1388",
"DDInter1590"
] | Pantoprazole | Rifampicin | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
837,
24,
463
]
],
[
[
837,
6,
7950
],
[
7950,
45,
463
]
],
[
[
837,
24,
542
],
[
542,
24,
463
]
],
[
[
837,
23,
1069
],
[
1069,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Pantoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compoun... | Pantoprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Rifampicin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Pantopra... |
DB00364 | DB04861 | 417 | 1,592 | [
"DDInter1717",
"DDInter1271"
] | Sucralfate | Nebivolol | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Minor | 0 | [
[
[
417,
23,
1592
]
],
[
[
417,
24,
115
],
[
115,
62,
1592
]
],
[
[
417,
24,
1450
],
[
1450,
63,
1592
]
],
[
[
417,
63,
1685
],
[
1685,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nebivolol"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Nebivolol
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Empaglif... |
DB00166 | DB00222 | 333 | 245 | [
"DDInter1076",
"DDInter825"
] | Lipoic acid | Glimepiride | A vitamin-like antioxidant. | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Minor | 0 | [
[
[
333,
23,
245
]
],
[
[
333,
23,
959
],
[
959,
1,
245
]
],
[
[
333,
23,
1645
],
[
1645,
63,
245
]
],
[
[
333,
62,
1685
],
[
1685,
... | [
[
[
"Lipoic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
]
],
[
[
"Lipoic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glipizide"
],
[
... | Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound)
Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Metformin and Metformin may cause a moderate interaction that could exac... |
DB00673 | DB01138 | 723 | 804 | [
"DDInter112",
"DDInter1726"
] | Aprepitant | Sulfinpyrazone | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
723,
24,
804
]
],
[
[
723,
24,
998
],
[
998,
1,
804
]
],
[
[
723,
6,
8374
],
[
8374,
45,
804
]
],
[
[
723,
63,
168
],
[
168,
23,... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfinpyrazone (Compound)
Aprepitant may cause a moderate interaction that c... |
DB01242 | DB06176 | 1,237 | 1,342 | [
"DDInter410",
"DDInter1616"
] | Clomipramine | Romidepsin | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1237,
24,
1342
]
],
[
[
1237,
62,
112
],
[
112,
23,
1342
]
],
[
[
1237,
63,
485
],
[
485,
24,
1342
]
],
[
[
1237,
24,
1616
],
[
1616,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Clomipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and... |
DB01229 | DB11989 | 973 | 1,434 | [
"DDInter1378",
"DDInter183"
] | Paclitaxel (protein-bound) | Benznidazole | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
973,
24,
1434
]
],
[
[
973,
24,
788
],
[
788,
24,
1434
]
],
[
[
973,
25,
375
],
[
375,
24,
1434
]
],
[
[
973,
24,
148
],
[
148,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Pa... |
DB00740 | DB01097 | 424 | 1,377 | [
"DDInter1596",
"DDInter1033"
] | Riluzole | Leflunomide | A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
424,
25,
1377
]
],
[
[
424,
7,
2602
],
[
2602,
45,
1377
]
],
[
[
424,
6,
7950
],
[
7950,
45,
1377
]
],
[
[
424,
18,
2049
],
[
2049,
... | [
[
[
"Riluzole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Riluzole",
"{u} (Compound) upregulates {v} (Gene)",
"PTK2B"
],
[
"PTK2B",
"{u} (Gene) is bound by {v} (Compound)",
"Leflun... | Riluzole (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) is bound by Leflunomide (Compound)
Riluzole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Leflunomide (Compound)
Riluzole (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Leflunomide (Compound)
Riluzole (Compound) c... |
DB01097 | DB08860 | 1,377 | 788 | [
"DDInter1033",
"DDInter1479"
] | Leflunomide | Pitavastatin | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Major | 2 | [
[
[
1377,
25,
788
]
],
[
[
1377,
64,
671
],
[
671,
1,
788
]
],
[
[
1377,
64,
700
],
[
700,
40,
788
]
],
[
[
1377,
6,
17404
],
[
17404,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitavastatin"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
... | Leflunomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin (Compound)
Leflunomide (Compo... |
DB00877 | DB11581 | 629 | 1,456 | [
"DDInter1678",
"DDInter1926"
] | Sirolimus | Venetoclax | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
629,
24,
1456
]
],
[
[
629,
63,
536
],
[
536,
24,
1456
]
],
[
[
629,
24,
259
],
[
259,
24,
1456
]
],
[
[
629,
24,
241
],
[
241,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilo... |
DB00427 | DB06077 | 1,233 | 879 | [
"DDInter1879",
"DDInter1102"
] | Triprolidine | Lumateperone | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
1233,
24,
879
]
],
[
[
1233,
24,
407
],
[
407,
63,
879
]
],
[
[
1233,
24,
1511
],
[
1511,
24,
879
]
],
[
[
1233,
63,
999
],
[
999,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzola... |
DB00514 | DB01114 | 506 | 272 | [
"DDInter527",
"DDInter362"
] | Dextromethorphan | Chlorpheniramine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
506,
24,
272
]
],
[
[
506,
24,
358
],
[
358,
63,
272
]
],
[
[
506,
63,
128
],
[
128,
24,
272
]
],
[
[
506,
6,
12523
],
[
12523,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadr... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with... |
DB08827 | DB14731 | 990 | 1,518 | [
"DDInter1085",
"DDInter1741"
] | Lomitapide | Tagraxofusp | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Major | 2 | [
[
[
990,
25,
1518
]
],
[
[
990,
64,
1324
],
[
1324,
24,
1518
]
],
[
[
990,
63,
170
],
[
170,
24,
1518
]
],
[
[
990,
24,
1281
],
[
1281,
... | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"... | Lomitapide may lead to a major life threatening interaction when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may... |
DB05316 | DB11901 | 749 | 913 | [
"DDInter1467",
"DDInter107"
] | Pimavanserin | Apalutamide | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
749,
24,
913
]
],
[
[
749,
62,
112
],
[
112,
23,
913
]
],
[
[
749,
63,
600
],
[
600,
24,
913
]
],
[
[
749,
24,
28
],
[
28,
24,
... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole an... |
DB00850 | DB01377 | 1,630 | 1,283 | [
"DDInter1432",
"DDInter1119"
] | Perphenazine | Magnesium oxide | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
1630,
23,
1283
]
],
[
[
1630,
1,
684
],
[
684,
23,
1283
]
],
[
[
1630,
35,
104
],
[
104,
23,
1283
]
],
[
[
1630,
63,
999
],
[
999,
... | [
[
[
"Perphenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may caus... | Perphenazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Perphenazine (Compound) resembles Methdilazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken w... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.